Targeted therapy in melanoma

Hussein Tawbi, Neelima NimmagaddaUniversity of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine, Pittsburg, PA, USAAbstract: Malignant melanoma is a highly lethal disease unless detected early. Single-agent chemotherapy is well tolerated but is associated with very low...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hussein Tawbi, Neelima Nimmagadda
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c226513164c24b1387ca66a40511f71d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c226513164c24b1387ca66a40511f71d
record_format	dspace
spelling	oai:doaj.org-article:c226513164c24b1387ca66a40511f71d2021-12-02T05:42:15ZTargeted therapy in melanoma1177-54751177-5491https://doaj.org/article/c226513164c24b1387ca66a40511f71d2009-10-01T00:00:00Zhttp://www.dovepress.com/targeted-therapy-in-melanoma-a3637https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Hussein Tawbi, Neelima NimmagaddaUniversity of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine, Pittsburg, PA, USAAbstract: Malignant melanoma is a highly lethal disease unless detected early. Single-agent chemotherapy is well tolerated but is associated with very low response rates. Combination chemotherapy and biochemotherapy may improve objective response rates but do not prolong survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients, but are impractical for many patients due to accessibility and toxicity issues. Elucidations of the molecular mechanisms of carcinogenesis in melanoma have expanded the horizon of opportunity to alter the natural history of the disease. Multiple signal transduction pathways seem to be aberrant and drugs that target them have been and continue to be in development. In this review we present data on the most promising targeted agents in development, including B-raf inhibitors and other signal transduction inhibitors, oligonucleotides, proteasome inhibitors, as well as inhibitors of angiogenesis. Most agents are in early phase trials although some have already reached phase III evaluation. As knowledge and experience with targeted therapy advance, new challenges appear to be arising particularly in terms of resistance and appropriate patient selection.Keywords: targeted therapy, metastatic melanoma, sorafenib, oblimersen, bevacizumab&nbsp; Hussein TawbiNeelima NimmagaddaDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 475-484 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hussein Tawbi Neelima Nimmagadda Targeted therapy in melanoma
description	Hussein Tawbi, Neelima NimmagaddaUniversity of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine, Pittsburg, PA, USAAbstract: Malignant melanoma is a highly lethal disease unless detected early. Single-agent chemotherapy is well tolerated but is associated with very low response rates. Combination chemotherapy and biochemotherapy may improve objective response rates but do not prolong survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients, but are impractical for many patients due to accessibility and toxicity issues. Elucidations of the molecular mechanisms of carcinogenesis in melanoma have expanded the horizon of opportunity to alter the natural history of the disease. Multiple signal transduction pathways seem to be aberrant and drugs that target them have been and continue to be in development. In this review we present data on the most promising targeted agents in development, including B-raf inhibitors and other signal transduction inhibitors, oligonucleotides, proteasome inhibitors, as well as inhibitors of angiogenesis. Most agents are in early phase trials although some have already reached phase III evaluation. As knowledge and experience with targeted therapy advance, new challenges appear to be arising particularly in terms of resistance and appropriate patient selection.Keywords: targeted therapy, metastatic melanoma, sorafenib, oblimersen, bevacizumab&nbsp;
format	article
author	Hussein Tawbi Neelima Nimmagadda
author_facet	Hussein Tawbi Neelima Nimmagadda
author_sort	Hussein Tawbi
title	Targeted therapy in melanoma
title_short	Targeted therapy in melanoma
title_full	Targeted therapy in melanoma
title_fullStr	Targeted therapy in melanoma
title_full_unstemmed	Targeted therapy in melanoma
title_sort	targeted therapy in melanoma
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c226513164c24b1387ca66a40511f71d
work_keys_str_mv	AT husseintawbi targetedtherapyinmelanoma AT neelimanimmagadda targetedtherapyinmelanoma
_version_	1718400256541982720

Targeted therapy in melanoma

Ejemplares similares